|Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Small-cell carcinoma.
|WikiProject Medicine / Hematology-oncology / Pathology / Pulmonology||(Rated C-class, High-importance)|
Link to prostate carcinoma
- Because small cell carcinoma can occur in the prostate as well as the lung. Theshowmecanuck (talk), 21:26, 23 January 2008 (UTC)
Please annotate photos of cells
I think it would be beneficial if someone could annotate the photos of the cancer cells to point out which are the cancer cells and which are the normal healthy cells (and possibly what type of cells they are). For most if not all non-medical and non-biology people, the pictures actually don't add much benefit to the article if we don't know what we are looking at. Not working in the medical or biology professions, I have no idea which are the cancer cells, but I am interested... if you can show me. I think the annotation should be done directly in the photo, not as a side bar... you cannot point directly to a cell for example and say it is 'x' type of cell from a side bar. Theshowmecanuck (talk) —Preceding undated comment added 20:47, 30 May 2010 (UTC).
The introduction could use expansion as per: 1st paragraph is a brief definition and signs/symptoms. 2nd paragraph is cause, mechanism of disease, and diagnosis. 3rd paragraph is prevention and treatment. 4th paragraph is epidemiology, prognosis, society and culture, and history. Lime0life (talk) 00:22, 25 February 2015 (UTC)
targeted therapies limited
Could mention sunitinib maintenance therapy as per : Small Cell Lung Cancer Treatment & Management. Winston. 2015 :
SCLC has not been shown to respond well to targeted therapies. Studies of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitors have yielded disappointing results: bevacizumab, aflibercept, and vandetanib have failed to demonstrate significant improvements in survival. However, a recent phase II trial of sunitinib maintenance therapy in patients with untreated extensive-stage SCLC reported a modest but significant improvement in median progression-free survival, from 2.1 months with placebo to 3.7 months with sunitinib.